Hologic, Inc. (NASDAQ:HOLX) insider Peter J. Valenti III sold 4,545 shares of Hologic stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $44.07, for a total transaction of $200,298.15. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
NASDAQ HOLX traded up $0.31 during trading on Friday, hitting $48.02. 2,093,057 shares of the company’s stock were exchanged, compared to its average volume of 1,749,319. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.02 and a current ratio of 1.45. The stock has a market capitalization of $12.75 billion, a P/E ratio of 21.53, a PEG ratio of 2.20 and a beta of 0.69. Hologic, Inc. has a fifty-two week low of $37.47 and a fifty-two week high of $49.78. The firm’s 50 day moving average price is $46.23.
Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, May 1st. The medical equipment provider reported $0.58 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.57 by $0.01. Hologic had a positive return on equity of 26.73% and a negative net margin of 0.32%. The firm had revenue of $818.40 million during the quarter, compared to the consensus estimate of $806.99 million. During the same quarter in the previous year, the firm earned $0.53 earnings per share. The business’s quarterly revenue was up 3.7% on a year-over-year basis. On average, equities analysts predict that Hologic, Inc. will post 2.42 earnings per share for the current year.
HOLX has been the subject of a number of recent research reports. TheStreet raised shares of Hologic from a “c” rating to a “b” rating in a research report on Monday, March 4th. Needham & Company LLC reissued a “buy” rating and issued a $50.00 target price on shares of Hologic in a research report on Tuesday, April 2nd. Zacks Investment Research raised shares of Hologic from a “hold” rating to a “buy” rating and set a $53.00 target price for the company in a research report on Tuesday, March 5th. BidaskClub cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 4th. Finally, BTIG Research reissued a “buy” rating and issued a $52.00 target price on shares of Hologic in a research report on Thursday, May 2nd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $45.02.
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
See Also: How is a price target determined?
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.